Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...

These non-alcoholic beverages include ingredients like nootropics and adaptogens which may boost your mood — without the ...

Experts say there’s been a rise in young people taking 'Xanax' recreationally in Australia. The drug is usually prescribed to ...

In states where both medical and recreational marijuana are legal, fewer patients are filling prescriptions for medications ...

By one estimate, 68% of Americans consume less than the recommended dietary amount of magnesium. Magnesium is essential for ...

Feeling down? What is on your plate might be playing a bigger role in your mood than you think. Depression is a growing ...

Researchers found spinal disinhibition in people with fibromyalgia, adding new clues about the role of central pain ...

Depression continues to grapple a large proportion of the population. Given the side effects associated with the long-term use of conventional antidepressants, there is a need for novel rapid acting ...

Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Chief Executive Officer Barry Greene will discuss the Company’s strategic focus areas for 2025 at the 43rd Annual J.P. Morgan Healthcare ...

A yearslong partner of neuroscience player Sage, Biogen already owns 10.2% of the Cambridge, Massachusetts-based biotech, ...

The global burden of anxiety- and depression-related disorders is on the rise. While multiple drugs have been developed to treat these conditions, current medications have several limitations, ...

The $7.22-per-share deal for 89.8% of Sage is a 30% premium on the company's share price on Friday and is estimated by ...